Live Breaking News & Updates on Feaganb Ozanimod

Stay updated with breaking news from Feaganb ozanimod. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® , an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1

Zeposia the first and only oral sphingosine 1-phosphate receptor modulator approved for ulcerative colitis 1 represents a new way of treating this chronic immune-mediated disease 2 Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement versus placebo at . ....

United States , Feaganb Ozanimod , Bristol Myers Squibb , Michael Chiorean , Adam Lenkowsky , National Institute Of Diabetes , Expert Group Consensus , Crohn Colitis Foundation , Bristol Myers Squibb Company , European Union , Centers For Disease , European Commission , Drug Administration , Exchange Commission , European Medicines Agency , Swedish Medical Center , True North Phase , Myers Squibb , Bristol Myers , True North , Important Safety Information , Michael Osso , Marketing Authorization Application , Multifocal Leukoencephalopathy , Atrioventricular Conduction Delays , Blood Pressure ,